汪 晴 李子敬 孙 璐 高丽英 李明慧 郝佳佳 张 欣 孙玉明. LC-MS方法研究氢溴酸高乌甲素在小鼠体内的药代动力学(英文)J. 药学学报, 2011,46(4): 432-437.
引用本文: 汪 晴 李子敬 孙 璐 高丽英 李明慧 郝佳佳 张 欣 孙玉明. LC-MS方法研究氢溴酸高乌甲素在小鼠体内的药代动力学(英文)J. 药学学报, 2011,46(4): 432-437.
HONG Qing, Li-Zi-Jing, Sun- Lu, Gao-Li-Yang, Li-Meng-Hui, Hao-Jia-Jia, Zhang- Xin, Sun-Yu-Meng. Pharmacokinetic study of lappaconitine hydrobromide in mice by LC-MSJ. 药学学报, 2011,46(4): 432-437.
Citation: HONG Qing, Li-Zi-Jing, Sun- Lu, Gao-Li-Yang, Li-Meng-Hui, Hao-Jia-Jia, Zhang- Xin, Sun-Yu-Meng. Pharmacokinetic study of lappaconitine hydrobromide in mice by LC-MSJ. 药学学报, 2011,46(4): 432-437.

LC-MS方法研究氢溴酸高乌甲素在小鼠体内的药代动力学(英文)

Pharmacokinetic study of lappaconitine hydrobromide in mice by LC-MS

  • 摘要:

    本文建立了一种快速、灵敏的LC-MS法用于检测小鼠血浆中的高乌甲素浓度。采用ESI源和多反应监测 (MRM) 的方式进行检测, 所选用的高乌甲素和内标延胡索乙素的反应离子对分别为m/z 585 → 535m/z 356 → m/z 192。该方法在3.02 000.0 ng·mL−1浓度内线性关系良好, 定量下限为3.0 ng·mL−1, 日内和日间精密度 (RSD) 均小于9.9%, 准确度 (RE) ± 4.8%之内。氢溴酸高乌甲素分别以1.02.04.0 mg·kg−1单剂量静脉注射给予小鼠后, t1/2分别为0.470.480.49 h, AUC0t分别为55.5110.5402.9 ng·h·mL−1。实验结果表明, 氢溴酸高乌甲素单剂量静脉注射给予小鼠后, 在低剂量 (1.02.0 mg·kg−1) 范围内其药动学行为符合线性动力学特征, 当给药剂量 (2.0 mg·kg−1) 增大至4.0 mg·kg−1, AUC增加至约4, VzCL却显著降低, 呈现非线性动力学特征, 可能与高浓度下药物血浆蛋白结合率的降低有关。

     

    Abstract:

    A high sensitive and rapid method was developed for the analysis of lappaconitine in mouse plasma using liquid chromatography coupled to mass spectrometry (LC-MS).  Detection was performed by positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode, monitoring the transitions m/z 585 → m/z 535 and m/z 356 → m/z 192, for the quantification of lappaconitine and tetrahydropalmatine (internal standard, IS), respectively.  The method was linear over the concentration range of 3.02 000.0 ng·mL−1.  The lower limit of quantification was 3.0 ng·mL−1.  Intra- and inter-run precisions (RSD) were both less than 9.9% and accuracy (RE) within ± 4.8%.  After single intravenous injections of lappaconitine hydrobromide at 1.0, 2.0 and 4.0 mg·kg−1, the elimination half-lives (t1/2) were 0.47, 0.48 and 0.49 h, and the areas under the curve (AUC0t) were 55.5, 110.5 and 402.9 ng·h·mL−1, separately.  The pharmacokinetic profile of lappaconitine was linear at relatively lower dose levels (1.02.0 mg·kg−1).  When the dose increased farther to 4.0 mg·kg−1, the Vz and CL decreased, and the increase fold of the AUC was much larger than that of the dose.

     

/

返回文章
返回